Idiopathic Pulmonary Fibrosis Progression
Veracyte has just signed a deal with Yale University which will help them develop the very first test which can predict disease progression for idiopathic pulmonary fibrosis (IPF).
The Envisia Classifier is a genomic tool for IPF diagnosis but it currently does not include details on prognosis. The addition of prognostic data will increase the benefits of this Classifier. The Envisia Classifier is a part of the nCounter FLEX Analysis System, developed by Veracyte. The team hopes to have the new prognostic test launched on the global platform by 2021.
Naftali Kaminski is the developer of this new tool. His work at Yale has focused on better understanding the genetics behind interstitial lung diseases like IPF. This understanding will improve knowledge on patient diagnosis, prognosis, and their individualized treatment.
The new prognostic tool is a simple, non-invasive blood test. This addition to the Envisia Classifier will make the entire tool a more comprehensive instrument.
Understanding prognosis is very important. If we know which patients are most likely to experience rapid disease progression, we can offer them the proper treatments in a more timely manner.
In terms of research, it will also allow scientists to better stratify patient cohorts for clinical trials. This could lead to more precise and tailored treatments for different categories of patients.
You can read more about this new tool here.